AVXS101 in SMA type 1 on track for launch in H1 2019, and clinical development underway in all other SMA subtypes Progressing cell, gene and radioligand therapy platforms with 13 therapies in clinical development, and 9 more expected to enter the clinic in 2019. The potentially foundational gene therapy AVXS101… Att fortsätt läsa
Novartis has now announced the price for gene therapy AVXS-101. Is it expected the cost 4 $ million – 5$ million per patient.
The next expensive treatment will be at some point a contention in our health system. Small countries like Denmark cannot afford the expensive medicine of Spinraza, what is then with this drug!
Although AVXS-101 is given once by single infusion, is the final price entitled!
Tell us what you think about this price. Share your thoughts below 👇
Cure SMA Canada speaks out for the rights of Canadians affected by Spinal Muscular Atrophy to access treatment All patients affected by SMA in Canada have a need and a right to treatment! I say, all patients affected by SMA in worldwide have a right to treatment! #AccessToSpinraza #TillgångTillSpinrazaFörAlla #SpinalMuskelatrofi… Att fortsätt läsa
Safety of intrathecal treatment with nusinersen therapy with spinal muscular atrophy SMA Typ 2/3 New study from University Essen shows great results University Essen treated a total of 28 adult SMA patients (9 patients with SMA type 2 and 19 patients with SMA type 3) aged between 18–61 years with nusinersen…. Att fortsätt läsa